All In Biotech

Drug Trial Radar · NCT02605174

Three Doses of Lasmiditan (50 mg, 100 mg and 200 mg) Compared to Placebo in the Acute Treatment of Migraine

A Study of Three Doses of Lasmiditan (50 mg, 100 mg and 200 mg) Compared to Placebo in the Acute TReaTment of MigrAiNe: A Randomized, Double-blind, Placebo-controlled Parallel Group Study (SPARTAN)

Last checked: Nov 20, 2026Latest source record: Sep 23, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 3,005 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

3,005

Actual

Start

May 2016

Primary completion

Jun 30, 2017

Study completion Jun 30, 2017

Sponsor

Lead sponsor
Eli Lilly and CompanyEli Lilly (LLY)
Sponsor type
Industry
Collaborators
CoLucid Pharmaceuticals
First posted
Nov 16, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Sequential
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a prospective randomized, double-blind, placebo-controlled study in participants with disabling migraine (Migraine Disability Assessment (MIDAS) score ≥ 11).

Conditions

  • Migraine With or Without Aura

Interventions

  • Lasmiditan 50 mgDrug

    One tablet lasmiditan 50 mg plus one placebo tablet (matching one of the lasmiditan doses)

  • Lasmiditan 100 mgDrug

    One tablet lasmiditan 100 mg plus one placebo tablet (matching one of the lasmiditan doses)

  • Lasmiditan 200 mgDrug

    One tablet lasmiditan 200 mg plus one placebo tablet (matching one of the lasmiditan doses)

  • PlaceboDrug

    Two placebo tablets to match lasmiditan doses.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants Headache Pain Free at 2 Hours Post DoseTime frame: 2 hours post dose
  2. Percentage of Participants Who Are Most Bothersome Symptom (MBS) FreeTime frame: 2 hours post dose

Locations

95 sites in 1 country. Site status is shown where the registry gives one.

  • Alabama Clinical Therapeutics, LLC

    Birmingham, Alabama

  • Medical Affiliated Research Center, Inc. - ARC

    Huntsville, Alabama

  • 21st Century Neurology

    Phoenix, Arizona

  • Anaheim Clinical Trials

    Anaheim, California

  • The Research Center of Southern California

    Carlsbad, California

  • eStudySite

    Chula Vista, California

  • Pharmacology Research Institute

    Los Alamitos, California

  • Pharmacology Research Institute, Newport Beach

    Newport Beach, California

  • Pacific Research Partners

    Oakland, California

  • Desert Valley Research

    Rancho Mirage, California

  • Northern California Clinical Research Center

    Redding, California

  • Anderson Clinical Research

    Redlands, California

  • California Research Foundation

    San Diego, California

  • Neurological Research Institute

    Santa Monica, California

  • Schuster Medical Research Institute

    Sherman Oaks, California

  • Encompass Clinical Research

    Spring Valley, California

  • Diablo Clinical Research, Inc.

    Walnut Creek, California

  • Lytle and Weiss, PLLC dba Clinical Trials of the Rockies

    Denver, Colorado

  • Comprehensive Psychiatric Care

    Norwich, Connecticut

  • Chase Medical Research, LLC

    Waterbury, Connecticut

  • Nova Clinical Reseach, LLC

    Bradenton, Florida

  • PAB Clinical Research

    Brandon, Florida

  • Meridien Research

    Brooksville, Florida

  • Avail Clinical Research, LLC

    DeLand, Florida

  • The Core Research

    Doral, Florida

  • Clinical Research West Coast

    Fort Myers, Florida

  • Indago Research & Health Center, Inc.

    Hialeah, Florida

  • Infinity Clinical Research, LLC

    Hollywood, Florida

  • Clinical Neuroscience Solutions, Inc.

    Jacksonville, Florida

  • Florida Clinical Research

    Maitland, Florida

  • Pharmax Research Clinic, Inc.

    Miami, Florida

  • Prestige Clinical Research Center, Inc.

    Miami, Florida

  • Floriday Medical Center and Research, Inc.

    Miami, Florida

  • Veritas Research Corporation

    Miami Lakes, Florida

  • Harmony Clinical Research Inc.

    North Miami Beach, Florida

  • Compass Research, LLC

    Orlando, Florida

  • Clinical Research Center, LLC

    Royal Palm Beach, Florida

  • Meridien Research, Inc.

    St. Petersburg, Florida

  • Meridian Clinical Research, LLC

    Tampa, Florida

  • Palm Beach Research Center

    West Palm Beach, Florida

Showing 40 of 95 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.